Literature DB >> 22466939

Disease-syndrome combination clinical study of psoriasis: present status, advantages, and prospects.

Chuan-Jian Lu1, Jing-Jie Yu, Jing-Wen Deng.   

Abstract

Psoriasis is an immune-abnormal, chronic, proliferative skin disease determined by polygenic inheritance and induced by a number of environmental factors. It causes worldwide concern because of its high-prevalence, harmful and incurable characteristics. Over the years, Chinese medicine (CM) treatment of psoriasis has accumulated a wealth of clinical experience. Disease-syndrome combination, which achieves more satisfactory clinical effect, is the basis to highlight the special CM advantages in treating psoriasis. In this paper, we review the advantages of treating psoriasis with the combination of disease and syndrome, analyze the prospects of research on treating psoriasis combining disease with syndrome. We also make a point that there are several key points for the clinical research of combination of disease and syndrome. It can be expected that carrying out clinical research on the combination of disease and syndrome will help improve the clinical efficacy of medical treatment of psoriasis, which will be the main direction of research in the future.

Entities:  

Mesh:

Year:  2012        PMID: 22466939     DOI: 10.1007/s11655-012-1006-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  9 in total

1.  The prevalence of psoriasis in the world.

Authors:  S P Raychaudhuri; E M Farber
Journal:  J Eur Acad Dermatol Venereol       Date:  2001-01       Impact factor: 6.166

2.  Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.

Authors:  Z He; C Lu; M K A Basra; A Ou; Y Yan; L Li
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-12-07       Impact factor: 6.166

3.  [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].

Authors:  L Puig; X Bordas; J M Carrascosa; E Daudén; C Ferrándiz; J M Hernanz; J L López-Estebaranz; J C Moreno; J L Sánchez-Carazo; F Vanaclocha; H Vázquez-Veiga
Journal:  Actas Dermosifiliogr       Date:  2009-05

Review 4.  What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.

Authors:  V Bronsard; C Paul; S Prey; E Puzenat; P-A Gourraud; S Aractingi; F Aubin; M Bagot; B Cribier; P Joly; D Jullien; M Le Maitre; M-A Richard-Lallemand; J-P Ortonne
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-04       Impact factor: 6.166

5.  The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.

Authors:  Yi-Ju Chen; Chun-Ying Wu; Tzeng-Ji Chen; Jui-Lung Shen; Szu-Ying Chu; Chang-Bi Wang; Yun-Ting Chang
Journal:  J Am Acad Dermatol       Date:  2011-03-31       Impact factor: 11.527

6.  Psoriasis and the metabolic syndrome.

Authors:  Mohammed Ahmed Alsufyani; Alexandra K Golant; Mark Lebwohl
Journal:  Dermatol Ther       Date:  2010 Mar-Apr       Impact factor: 2.851

7.  What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region.

Authors:  Amaro García-Diez; Carlos Ferrandiz Foraster; Francisco Vanaclocha Sebastián; Luis Lizán Tudela; Xavier Badia Llach; Guillermo Sellers Fernández
Journal:  Dermatology       Date:  2008-01-23       Impact factor: 5.366

8.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Authors:  Alan Menter; Alice Gottlieb; Steven R Feldman; Abby S Van Voorhees; Craig L Leonardi; Kenneth B Gordon; Mark Lebwohl; John Y M Koo; Craig A Elmets; Neil J Korman; Karl R Beutner; Reva Bhushan
Journal:  J Am Acad Dermatol       Date:  2008-05       Impact factor: 11.527

9.  [Qinzhu Liangxue Decoction in treatment of blood-heat type psoriasis vulgaris: a randomized controlled trial].

Authors:  Fu-lun Li; Bin Li; Rong Xu; Xun Song; Yang Yu; Zheng-cheng Xu
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2008-06
  9 in total
  7 in total

1.  Oral Taodan granules for mild-to-moderate psoriasis vulgaris: protocol for a randomized, double-blind, multicenter clinical trial.

Authors:  Yi Ru; Xiao-Ning Yan; Su-Qing Yang; Li-Ping Gong; Ling-E Li; Jie Chen; Yi-Ding Zhao; Yue-Peng An; Gang Huang; Jin-Fang Zhang; Qing-Feng Yin; Rui-Ping Wang; Xin Li; Bin Li
Journal:  Ann Transl Med       Date:  2019-09

2.  Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial.

Authors:  Shefton Parker; Anthony Lin Zhang; Claire Shuiqing Zhang; Greg Goodman; Zehuai Wen; Chuanjian Lu; Charlie Changlie Xue
Journal:  Trials       Date:  2014-12-19       Impact factor: 2.279

3.  Auricular acupressure as a complementary therapy for psoriasis vulgaris: study protocol for a multicenter randomized controlled trial.

Authors:  Jingwen Deng; Chuanjian Lu; Yu Xiang; Hao Deng; Zehuai Wen; Danni Yao; Meiling Xuan; Yuhong Yan
Journal:  Trials       Date:  2019-06-17       Impact factor: 2.279

4.  The Gene Expression Analysis of Peripheral Blood Monocytes From Psoriasis Vulgaris Patients With Different Traditional Chinese Medicine Syndromes.

Authors:  Yue Lu; Yao Qi; Li Li; Yuhong Yan; Jianan Wei; Danni Yao; Jingjing Wu; Hao Deng; Jingwen Deng; Shuyan Ye; Haiming Chen; Qubo Chen; Hengjun Gao; Ling Han; Chuanjian Lu
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

5.  'Psoriasis 1' reduces psoriasis‑like skin inflammation by inhibiting the VDR‑mediated nuclear NF‑κB and STAT signaling pathways.

Authors:  Wen Sun; Yang Gao; Xianhua Yu; Yuan Yuan; Jun Yi; Zhen Zhang; Yuxing Cheng; Yong Li; Xing Peng; Xushan Cha
Journal:  Mol Med Rep       Date:  2018-07-09       Impact factor: 2.952

6.  Analysis of microRNA expression in peripheral blood monocytes of three Traditional Chinese Medicine (TCM) syndrome types in psoriasis patients.

Authors:  Yue Lu; Yao Qi; Yuhong Yan; Danni Yao; Hao Deng; Jingwen Deng; Shuyan Ye; Haiming Chen; Qubo Chen; Hengjun Gao; Ling Han; Chuanjian Lu
Journal:  Chin Med       Date:  2020-05-01       Impact factor: 5.455

7.  Oral Chinese herbal medicine for psoriasis vulgaris: protocol for a randomised, double-blind, double-dummy, multicentre clinical trial.

Authors:  Jingwen Deng; Danni Yao; Chuanjian Lu; Zehuai Wen; Yuhong Yan; Ziyang He; Huimei Wu; Hao Deng
Journal:  BMJ Open       Date:  2017-11-03       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.